Cataract device safety check: 20-Month Follow-Up study launches

NCT ID NCT07246915

ENROLLING_BY_INVITATION Disease control Sponsor: Edinburgh Biosciences Ltd Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 13, 2026 · Updated 19 times

Summary

This study follows 61 people who previously used the REVISYON SDS 100 device for mild-to-moderate cataract. Researchers will track side effects and vision changes over about 20 months to see if the device remains safe and effective. Participants do not receive any new treatment—only routine check-ups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dr. Berghian Ophthalmology Clinic

Timișoara, Romania
Institutul Clinic de Urgențe Oftalmologice Prof. Dr. Mircea Olteanu

Bucharest, Romania
Opticlass Clinic

Timișoara, Romania
Romania Clinica Vista, Ophtalmology Department

Timișoara, Romania
Spitalul Clinic CF Timisoara, Ophthalmology Department

Timișoara, Romania
Vedis Ophthalmology Clinic | Ophthalmological Center Dr. Samoila

Cluj-Napoca, Romania

Conditions

Explore the condition pages connected to this study.